Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sangchai Yingsakmongkon is active.

Publication


Featured researches published by Sangchai Yingsakmongkon.


Antimicrobial Agents and Chemotherapy | 2008

Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases

Keiko Hata; Koichi Koseki; Kazunori Yamaguchi; Setsuko Moriya; Yasuo Suzuki; Sangchai Yingsakmongkon; Go Hirai; Mikiko Sodeoka; Mark von Itzstein; Taeko Miyagi

ABSTRACT Oseltamivir (Tamiflu) and zanamivir (Relenza), two extensively used clinically effective anti-influenza drugs, are viral sialidase (also known as neuraminidase) inhibitors that prevent the release of progeny virions and thereby limit the spread of infection. Recently mortalities and neuropsychiatric events have been reported with the use of oseltamivir, especially in pediatric cases in Japan, suggesting that these drugs might also inhibit endogenous enzymes involved in sialic acid metabolism, including sialidase, sialyltransferase, and CMP-synthase, in addition to their inhibitory effects on the viral sialidase. The possible inhibition could account for some of the rare side effects of oseltamivir. However, there has been little direct evidence in regard to the sensitivities of animal sialidases to these drugs. Here, we examined whether these inhibitors might indeed affect the activities of human sialidases, which differ in primary structures and enzyme properties but possess tertiary structures similar to those of the viral enzymes. Using recombinant enzymes corresponding to the four human sialidases identified so far, we found that oseltamivir carboxylate scarcely affected the activities of any of the sialidases, even at 1 mM, while zanamivir significantly inhibited the human sialidases NEU3 and NEU2 in the micromolar range (Ki, 3.7 ± 0.48 and 12.9 ± 0.07 μM, respectively), providing a contrast to the low nanomolar concentrations at which these drugs block the activity of the viral sialidases.


Bioorganic & Medicinal Chemistry | 2009

Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties.

Jun-Ichi Sakamoto; Tetsuo Koyama; Daisei Miyamoto; Sangchai Yingsakmongkon; Kazuya I.-P. Jwa Hidari; Wipawee Jampangern; Takashi Suzuki; Yasuo Suzuki; Yasuaki Esumi; Takemichi Nakamura; Ken Hatano; Daiyo Terunuma; Koji Matsuoka

In order to develop novel influenza sialidase inhibitors, we constructed a library of glycoclusters composed of twelve types of sialylated dendrimers with thioglycosidic linkage that are resistant to hydrolysis by the sialidases. These sialodendrimers were synthesized by condensation reaction between a thiosialoside modified on the aglycon terminal end by a thioacetyl group and twelve types of carbosilane dendrimers having brominated terminal ends under deacetylation conditions, and temporal re-protection was performed for purification. Removal of all protection of the glycodendrimers was accomplished by transesterification and subsequent saponification to provide corresponding water-soluble glycodendrimers in good yields. For investigation of the structure-activity relationship, dendrimer scaffolds having differences in number of the sugar moieties, such as 3-, 4-, 6- and 12-functionalized dendrimers, and in linkage patterns, such as normal aliphatic linkage, ether- and amide-linkages. Biological evaluations of these glycodendrimers showed that all of the ether- and amide-elongated compounds had inhibitory potencies for the influenza sialidases in the mM range, while compounds having normal aliphatic linkage did not have any activities except for a 12-functionalized compound.


Emerging Infectious Diseases | 2015

Surveillance for Ebola Virus in Wildlife, Thailand.

Supaporn Wacharapluesadee; Kevin J. Olival; Budsabong Kanchanasaka; Prateep Duengkae; Supakarn Kaewchot; Phimchanok Srongmongkol; Gittiyaporn Ieamsaard; Patarapol Maneeorn; Nuntaporn Sittidetboripat; Thongchai Kaewpom; Sininat Petcharat; Sangchai Yingsakmongkon; Pierre E. Rollin; Jonathan S. Towner; Thiravat Hemachudha

To the Editor: Active surveillance for zoonotic pathogens in wildlife is particularly critical when the pathogen has the potential to cause a large-scale outbreak. The recent outbreak of Ebola virus (EBOV) disease in West Africa in 2014 was initiated by a single spillover event, followed by human-to-human transmission (1). Projection of filovirus ecologic niches suggests possible areas of distribution in Southeast Asia (2). Reston virus was discovered in macaques exported from the Philippines to the United States in 1989 and in sick domestic pigs in the Philippines in 2008 (with asymptomatic infection in humans) (3). Dead insectivorous bats in Europe were found to be infected by a filovirus, similar to other members of the genus Ebolavirus (4). Although EBOV has historically been viewed as a virus from Africa, recent studies found that bat populations in Bangladesh and China contain antibodies against EBOV and Reston virus recombinant proteins, which suggests that EBOVs are widely distributed throughout Asia (5,6). Thus, an outbreak in Asian countries free of EBOV diseases may not only be caused by importation of infected humans and/or wildlife from Africa but may arise from in-country filovirus–infected wildlife. Serologic and molecular evidence for filoviruses suggests that members of the order Chiroptera (bats) may be their natural reservoir (7). As part of a proactive biosurveillance program, we conducted a cross-sectional study for EBOV infection in bats and macaques in Thailand. We screened 500 Pteropus lylei bats collected from 10 roosting sites during March–June 2014 (Technical Appendix Figure) for antibodies against EBOV antigen by using an ELISA validated by the Centers for Disease Control and Prevention (Atlanta, GA, USA) (8). Bats and macaques were captured with permission from the Department of National Parks, Wildlife and Plant Conservation. The Institutional Animal Care and Use Committee at the University of California, Davis (protocol #16048) approved the capture and sample collection protocols. To further screen a wide range of wildlife species in Thailand for active EBOV infection, we sampled and tested 699 healthy bats, representing 26 species, and 50 long-tailed macaques (Macaca fascicularis). Additional bat species were randomly captured (≥50/site) in 6 provinces in Thailand during 2011–2013 and identified by morphologic traits. Macaques were captured and sampled in March 2013 from 1 site at Khao Chakan, Sa Kaeo Province, and released at the same site. Blood, saliva, urine, and feces were collected from anesthetized macaques or nonanesthetized bats. All animals were released after sample collection. Details on species screened, sample sizes, and trapping localities are provided in the Table. Table Overview of bats and macaques tested by Ebola virus IgG ELISA or PCR for filoviruses, Thailand, 2011–2014 All nonblood specimens were collected in nucleic acid extraction buffer (lysis buffer) and transported on ice to the World Health Organization Collaborating Centre for Research and Training on Viral Zoonoses laboratory (Bangkok, Thailand) for storage and testing. Three types of specimen (saliva, urine, and serum) were collected from individual animals and pooled. Nucleic acid was then extracted with NucliSENS easyMAG (bioMerieux, Boxtel, the Netherlands) and analyzed by reverse transcription PCR (RT-PCR). A consensus RT-PCR was used to screen for all known species of Ebola virus and Marburg virus, including EBOV (9). In total, 5 RT-PCRs were performed on each specimen, a regimen that included 4 sets of primers specific to known filoviruses and 1 degenerate primer set to detect novel viruses in this family. The sensitivity of RT-PCR on synthetic standard was 50–500 copies/reaction (9). We ran 3,745 PCRs, covering a range of assays, to increase detection sensitivity. All specimens examined were negative for filoviruses by EBOV ELISA and PCR (Table). For P. lylei ELISA screening, optical density values for all 500 bats ranged from 0.000 to 0.095, well below the potential positive cutoff value of 0.2. Assuming a population size of ≈5,000 bats/roost and a sample size of 50 bats/site, we have 95% confidence that if >6% of the population had antibodies against EBOV antigen, we would have detected it. If we assume that all 500 animals are part of 1 large panmictic population, and we have 95% confidence that if EBOV were circulating in >0.5% of the population, we would have detected it. Therefore, although we cannot rule out infection of this species with 100% confidence, P. lylei bats, the most abundant species of large pteropid bats in Thailand, are highly unlikely to be reservoirs for EBOV. Our sample sizes for PCR screening of other bat species in this study were much smaller, and we had no supported serologic data, but these negative results could add to the knowledge of filovirus infection in nontissue specimens from healthy bats. Previous studies have detected Ebola virus–like filovirus RNA in lung tissue of healthy Rousettus leschenaultia bats in China (10) and from organs and throat and rectal swab specimens from a die-off of Miniopterus schreibersii bats in Spain (4). In our study, which included 22 M. schreibersii and 132 M. magnate bats, none of the bats tested positive for filoviruses.One limitation of the cross-sectional sampling strategy used here, however, is that PCR-negative findings do not necessarily mean that the bats were not infected in the past. Although we found no evidence of filovirus infection in wildlife species tested in Thailand, we believe that continuing targeted surveillance in wildlife should enable early detection and preparedness to preempt emerging zoonoses. Technical Appendix. Map showing 20 Pteropus lylei bat roosting sites (gray circles, update 2015) in Thailand from 10 years of population surveys by the Department of National Parks, Wildlife and Plant Conservation and Kasetsart University, Thailand. These bats form large, colonial aggregations of individual animals, which often roost near human dwellings and primarily in the central region of the country. The map shows that populations of this species are concentrated in Central Thailand. Ten sampling sites (black star) included in the current study, March–June 2014, were selected on the basis of the size of the bat population, >2,000 bats/colony (50 individual bats sampled/locality). Abbreviations indicate provinces where P. lylei bats were found: AT, Ang Thong; AY, Phra Nakhon Si Ayutthaya; BK, Bangkok; CH, Chonburi; CHS, Chachoengsao; NY, Nakhon Nayok; PBR, Prachinburi; SAK, Srakaeo; SB, Saraburi; SH, Singburi; SMR, Samut Sakhon; SP, Suphan Buri. Click here to view.(149K, pdf)


Biological & Pharmaceutical Bulletin | 2008

In Vitro Inhibition of Human Influenza A Virus Infection by Fruit-Juice Concentrate of Japanese Plum (Prunus mume S IEB . et Z UCC )

Sangchai Yingsakmongkon; Daisei Miyamoto; Nongluk Sriwilaijaroen; Kimie Fujita; Kosai Matsumoto; Wipawee Jampangern; Hiroaki Hiramatsu; Chao-Tan Guo; Toshihiko Sawada; Tadanobu Takahashi; Kazuya I.-P. Jwa Hidari; Takashi Suzuki; Morihiro Ito; Yasuhiko Ito; Yasuo Suzuki


Biological & Pharmaceutical Bulletin | 2008

Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.

Daisei Miyamoto; Sayaka Hasegawa; Nongluk Sriwilaijaroen; Sangchai Yingsakmongkon; Hiroaki Hiramatsu; Tadanobu Takahashi; Kazuya I.-P. Jwa Hidari; Chao-Tan Guo; Yuichi Sakano; Takashi Suzuki; Yasuo Suzuki


Bioorganic & Medicinal Chemistry Letters | 2007

Thiosialoside clusters using carbosilane dendrimer core scaffolds as a new class of influenza neuraminidase inhibitors

Jun-Ichi Sakamoto; Tetsuo Koyama; Daisei Miyamoto; Sangchai Yingsakmongkon; Kazuya I.-P. Jwa Hidari; Wipawee Jampangern; Takashi Suzuki; Yasuo Suzuki; Yasuaki Esumi; Ken Hatano; Daiyo Terunuma; Koji Matsuoka


Bioorganic & Medicinal Chemistry Letters | 2007

Novel linear polymers bearing thiosialosides as pendant-type epitopes for influenza neuraminidase inhibitors

Koji Matsuoka; Chiharu Takita; Tetsuo Koyama; Daisei Miyamoto; Sangchai Yingsakmongkon; Kazuya I.-P. Jwa Hidari; Wipawee Jampangern; Takashi Suzuki; Yasuo Suzuki; Ken Hatano; Daiyo Terunuma


Virology Journal | 2015

Diversity of coronavirus in bats from Eastern Thailand

Supaporn Wacharapluesadee; Prateep Duengkae; Apaporn Rodpan; Thongchai Kaewpom; Patarapol Maneeorn; Budsabong Kanchanasaka; Sangchai Yingsakmongkon; Nuntaporn Sittidetboripat; Chaiyaporn Chareesaen; Nathawat Khlangsap; Apisit Pidthong; Kumron Leadprathom; Siriporn Ghai; Jonathan H. Epstein; Peter Daszak; Kevin J. Olival; Patrick J. Blair; Michael V. Callahan; Thiravat Hemachudha


Southeast Asian Journal of Tropical Medicine and Public Health | 2007

Detection of Campylobacter in duck using standard culture method and multiplex polymerase chain reaction.

Sumalee Boonmar; Sangchai Yingsakmongkon; Thavesak Songserm; Porama Hanhaboon; Wanida Passadurak


Southeast Asian Journal of Tropical Medicine and Public Health | 2005

Clinical differences among PCR-proven dengue serotype infections.

Kriengsak Limkittikul; Sangchai Yingsakmongkon; Akanitt Jittmittraphap; Somchai Chuananon; Yuphin Kongphrai; Surasak Kowasupathr; Chaiyaporn Rojanawatsirivit; Mammen P. Mammen; Wipawee Jampangern

Collaboration


Dive into the Sangchai Yingsakmongkon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge